Related Experiment Video
Updated: Oct 2, 2025
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
5.3K
Antiplatelet Agents in Acute ST Elevation Myocardial Infarction
1Oregon Health and Science University, Portland, Ore.
The American Journal of Medicine
|February 24, 2022
Summary
Platelet inhibitors reduce aggregation and thrombus formation, crucial in acute coronary syndromes. This review covers their mechanisms, pharmacodynamics, and clinical trials guiding ST elevation myocardial infarction treatment.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Platelet aggregation and thrombus formation are central to acute coronary syndromes (ACS).
- Atherosclerotic plaque rupture triggers these events, leading to clinical and biomarker changes.
- Platelet function inhibitors are key therapeutic agents in managing ACS.
Purpose of the Study:
- To review the mechanisms of action for various platelet inhibitors.
- To discuss their pharmacokinetics and pharmacodynamics.
- To examine key clinical trials informing current treatment guidelines for ST elevation myocardial infarction (STEMI).
Main Methods:
- Literature review of platelet inhibitors.
- Analysis of pharmacokinetic and pharmacodynamic data.
- Evaluation of pivotal clinical trials in STEMI.
Main Results:
- Overview of different oral and intravenous platelet inhibitor formulations.
- Summary of their efficacy in reducing platelet aggregation.
- Identification of evidence supporting their use in STEMI.
Conclusions:
- Platelet inhibitors are essential in managing STEMI.
- Understanding their properties guides optimal therapeutic strategies.
- Current guidelines emphasize their role based on robust clinical trial data.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
680
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
680
01:30Acute Coronary Syndrome I: Introduction
103
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
103
01:28Acute Coronary Syndrome IV: Interprofessional Care
44
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
44
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
67
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
67
01:27Coronary Artery Disease V: Interprofessional Care
53
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
53
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
745
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
745